Subscribe: pubmed: "Journal of controll...
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=0vmFlUlmdcwb4_6wisYf0gHKCjOKVyyfarC3zncT_nD
Preview: pubmed: "Journal of controll...

pubmed: "Journal of controll...



NCBI: db=pubmed; Term=("Journal of controlled release : official journal of the Controlled Release Society"[Jour])



 



Biocompatible polymer microneedle for transdermal delivery of tranexamic acid.
Related Articles

Biocompatible polymer microneedle for transdermal delivery of tranexamic acid.

J Control Release. 2017 Jun 20;:

Authors: Machekposhti SA, Soltani M, Najafizadeh P, Ebrahimi SA, Chen P

Abstract
Recently-introduced biocompatible polymeric microneedles offer an efficient method for drug delivery. Tranexamic acid is a novel drug for treating melasma that is administered both locally and orally and inhibits excessive melanin via melanocyte. The tranexamic acid biocompatible polymer microneedle used in this study was fabricated from PVP and methacrylic acid, using the lithography method. The required mechanical strength to pierce skin was attained by optimizing the ratio of PVP to methacrylic acid. Acute dermal toxicity was done, and drug diffusion in skin layers was simulated by calculating the diffusion coefficient of tranexamic acid in interstitial fluid (plasma). The biocompatible polymer microneedle was fabricated at 60°C. Needles could sustain 0.6N that is enough to pierce stratum corneum. 34% of the released drug was locally effective and the rest permeated through the skin. The pyramidal polymer microneedle in this study was fully released in skin in approx. 7h. This polymer microneedle has no dermal toxicity.

PMID: 28645793 [PubMed - as supplied by publisher]